Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxygen-driven versus air-driven nebulisers in severe COPD
ACTRN12610000080022Phase 3Not yet recruiting
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of salbutamol and ipratropium bromide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Medical Research Institute of New Zealand. Primary endpoint: Change in transcutaneous carbon dioxide level. Planned start Feb 2010; status: not yet recruiting.
02
Drugs
salbutamolipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12610000080022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000080022.